Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shuang Zhang, Min Yu & Yuquan Wei. (2014) Do anti-angiogenic cancer therapies increase risk of significant weight loss?. Expert Opinion on Drug Safety 13:4, pages 473-482.
Read now
Read now
Iben Kümler & Dorte Lisbet Nielsen. (2012) Trials of bevacizumab in breast cancer – a safety review. Expert Opinion on Drug Safety 11:sup1, pages S37-S48.
Read now
Read now
Stephan Michels, Franz Prager, Sophie J Bakri & Joachim Wachtlin. (2007) Bevacizumab for ophthalmic diseases. Expert Review of Ophthalmology 2:3, pages 369-378.
Read now
Read now
Philippe A. Coucke, Markus Notter, Maurice Matter, Fabrizio Fasolini, Jean-Marie Calmes, Rolph Schlumpf, Norbert Schwegler, Bernhard Stamm, Hu Phuoc Do & Hanifa Bouzourene. (2006) Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): Is it a matter of days?. Acta Oncologica 45:8, pages 1086-1093.
Read now
Read now
Articles from other publishers (21)
Xueyang Zheng, Na Li, Yong Xu, Chuanxin Zhang, Yueping Ouyang & Depeng Meng. (2022) A bilayer collagen scaffold with bevacizumab stabilizes chondrogenesis and promotes osteochondral regeneration. Materials & Design 221, pages 110981.
Crossref
Crossref
Jean Bouquet de Joliniere, Arrigo Fruscalzo, Fathi Khomsi, Emanuela Stochino Loi, Floryn Cherbanyk, Jean Marc Ayoubi & Anis Feki. (2021) Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report. Frontiers in Surgery 8.
Crossref
Crossref
Christoph Schulz, Volker Heinemann, Kathrin Heinrich, Michael Haas, Julian W. Holch, Alessia Fraccaroli, Swantje Held, Jobst C. von Einem, Dominik P. Modest, Ludwig Fischer von Weikersthal, Frank Kullmann, Markus Moehler, Werner Scheithauer, Andreas Jung & Sebastian Stintzing. (2020) Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer. Anti-Cancer Drugs Publish Ahead of Print.
Crossref
Crossref
Leo Mascarenhas, Yueh-Yun Chi, Pooja Hingorani, James R. Anderson, Elizabeth R. Lyden, David A. Rodeberg, Daniel J. Indelicato, Simon C. Kao, Roshni Dasgupta, Sheri L. Spunt, William H. Meyer & Douglas S. Hawkins. (2019) Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group. Journal of Clinical Oncology 37:31, pages 2866-2874.
Crossref
Crossref
Evan A. Thackaberry, Florence Lorget, Cindy Farman & Vladimir Bantseev. (2019) The safety evaluation of long-acting ocular delivery systems. Drug Discovery Today 24:8, pages 1539-1550.
Crossref
Crossref
Annalisa Guida, Laura Cosmai, Fabio Gelsomino, Cristina Masini, Roberto Sabbatini & Camillo Porta. (2016) Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality. EMJ Nephrology, pages 66-77.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
963
965
.
Nicholas A. Butowski & Susan M. Chang. 2012. Neuro-Oncology Part II. Neuro-Oncology Part II
937
945
.
Jean M. Torrisi, Lawrence H. Schwartz, Marc J. Gollub, Michelle S. Ginsberg, George J. Bosl & Hedvig Hricak. (2011) CT Findings of Chemotherapy-induced Toxicity: What Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy Toxicity. Radiology 258:1, pages 41-56.
Crossref
Crossref
Dorte Lisbet Nielsen, Michael Andersson, Jon Lykkegaard Andersen & Claus Kamby. (2010) Antiangiogenic therapy for breast cancer. Breast Cancer Research 12:5.
Crossref
Crossref
Herbert B. Newton. 2010. Glioblastoma. Glioblastoma
1
42
.
Herbert B. Newton. (2009) Bevacizumab: Review of Development, Pharmacology, and Application to Brain Tumors. Clinical Medicine. Therapeutics 1, pages CMT.S2042.
Crossref
Crossref
F.A. Goumas, F. Braun, D.C. Broering & M. Behrend. 2009.
589
618
.
Hironobu Minami, Kenji Kawada, Hiromichi Ebi, Koichi Kitagawa, Yon-il Kim, Kazuhiro Araki, Hirofumi Mukai, Makoto Tahara, Hikaru Nakajima & Keiko Nakajima. (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Science 99:7, pages 1492-1498.
Crossref
Crossref
Christos Emmanouilides, Dimitrios Philippou, Evdoxia Sapountzi & Eleni Diamandidou. (2008) Preliminary experience with bevacizumab in combination with standard chemotherapeutic regimens in the treatment of non-small cell lung cancer: a retrospective study. Hematology/Oncology and Stem Cell Therapy 1:3, pages 183-188.
Crossref
Crossref
James E Frampton & Gillian M Keating. (2008) Bevacizumab. BioDrugs 22:2, pages 113-120.
Crossref
Crossref
H Verheul, M Belderbos, R Pili & H Pinedo. 2007. Cancer-Associated Thrombosis. Cancer-Associated Thrombosis
77
95
.
Fiona H. Blackhall. (2007) E11-03: Controversy in small cell lung cancer: targeted therapy. Journal of Thoracic Oncology 2:8, pages S251-S253.
Crossref
Crossref
Debra Kamstock, Robyn Elmslie, Douglas Thamm & Steven Dow. (2007) Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunology, Immunotherapy 56:8, pages 1299-1309.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematology 62:3, pages 179-213.
Crossref
Crossref
Fiona H Blackhall & Frances A Shepherd. (2007) Small cell lung cancer and targeted therapies. Current Opinion in Oncology 19:2, pages 103-108.
Crossref
Crossref